Skip to main content
SpringerLink
Log in

Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

We sought to evaluate the activity and safety of carfilzomib-/ixazomib-containing combinations for patients with relapsed/refractory multiple myeloma (RRMM). We searched published reports including carfilzomib-/ixazomib-containing combinations for RRMM. Finally, we identified 11 prospective studies covering 2845 relapsed/refractory patients. Carfilzomib- and ixazomib-containing combinations respectively resulted in an impressive overall response rate (ORR 77 vs. 64%, P = 0.14), very good partial response or better (≥ VGPR 48 vs. 21%, P = 0.001), complete response or better (≥ CR 14 vs. 7%, P = 0.23), and clinical benefit rate (CBR 84 vs. 59%, P = 0.0002). Subgroup analysis showed that the carfilzomib (CFZ) +lenalidomide (LEN) + dexamethasone (DEX) triplet regimen resulted into similar response outcomes to those from CFZ + DEX doublet regimen in ORR (77 vs. 78%, P = 0.91), ≥VGPR (50 vs. 53%, P = 0.84), and ≥ CR (13 vs. 12%, P = 0.96) analysis in these previously heavily pretreated population. And, there were no statistically significant differences between IXA + LEN + DEX triplet regimen and CFZ + LEN + DEX triplet regimen in ORR (85 vs. 78%, P = 0.55), ≥ VGPR (37 vs. 53%, P = 0.19), and ≥ CR (18 vs. 12%, P = 0.70) analysis. There were favorable trend towards proteasome inhibitors (PIs) + IMiDs + DEX in comparison with PIs + alkylating agent + Dex in ORR (79 vs 49%, P < 0.00001), ≥ VGPR analysis (36 vs. 16%, P = 0.008), and ≥ CR (16 vs. 3%, P < 0.00001). Compared with current standard chemotherapy, carfilzomib containing combinations clearly improved overall survival (HR, 0.79; P = 0.01), progression free survival (HR, 0.61; P = 0.0001). Carfilzomib-/ixazomib-containing combinations produced clinical benefit for patients with R/RMM. PIs + IMiDs + DEX triplet regimens could be good options for such relapsed/refractory patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5):2516–2520

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J et al (2012) Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 26(1):149–157

    Article  CAS  PubMed  Google Scholar 

  3. Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV et al (2004) Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 79(7):867–874

    Article  CAS  PubMed  Google Scholar 

  4. Berdeja JG, Hart LL, Mace JR, Arrowsmith ER, Essell JH, Owera RS et al (2015) Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. Haematologica 100(5):670–676

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Berenson JR, Cartmell A, Bessudo A, Lyons RM, Harb W, Tzachanis D et al (2016) CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood 127(26):3360–3368

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E et al (2013) Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood 122(18):3122–3128

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Fiala MA, Keller J, Sekhar J, Ceriotti C, Abboud CN, DiPersio JF et al (2016) A phase II study of carfilzomib, pegylated liposomal doxorubicin, and dexamethasone for relapsed or refractory multiple myeloma. Blood 128:3329

    Google Scholar 

  8. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A et al (2015) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372(2):142–152

    Article  PubMed  Google Scholar 

  9. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R et al (2016) Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17(1):27–38

    Article  CAS  PubMed  Google Scholar 

  10. Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M et al (2014) Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol 15(13):1503–1512

    Article  CAS  PubMed  Google Scholar 

  11. Ludwig H, Gunsilius E, Fridrik M, Greil R, Petzer A, Kühr T et al (2016) Ixazomib, thalidomide and dexamethasone (IxaThalDex) in relapsed/refractory multiple myeloma (RRMM): an interim analysis of a phase II trial. Blood 128:3335

    Google Scholar 

  12. Kumar S, Grzasko N, Delimpasi S, Jędrzejczak WW, Grosicki S, Kyrtsonis M-C et al (2016) Phase 2 study of the all-oral combination of ixazomib plus cyclophosphamide and low-dose dexamethasone (ICd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM). Blood 128:3327

    Google Scholar 

  13. Kumar SK, LaPlant BR, Reeder CB, Roy V, Halvorson AE, Buadi F et al (2016) Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood 128:2415–2422

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L et al (2016) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374(17):1621–1634

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Weifang People’s Hospital, Weifang, China

    Wenjun Xu & Baohong Wang

  2. Department of Joint Surgery, Weifang People’s Hospital, Weifang, China

    Xuedong Sun

  3. Department of Neurosurgery, Weifang People’s Hospital, Weifang, China

    Hui Guo

Authors
  1. Wenjun Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xuedong Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Baohong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hui Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hui Guo.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Appendix

Appendix

Fig. 5
figure 5

Subgroup analysis of response rates derived from PIs + IMiDs + DEX vs. PIs + alkylating agent + DEX for relapsed/refractory multiple myeloma. (5.1.1, 5.1.2) Overall response rate (ORR) from PIs + IMiDs + DEX and PIs + alkylating agent + DEX. (5.2.1, 5.2.2) Very good partial response rate or better (≥ VGPR) from PIs + IMiDs + DEX and PIs + alkylating agent + DEX. (5.3.1, 5.3.2) Complete response or better rate (≥ CR) from PIs + IMiDs + DEX and PIs + alkylating agent + DEX. (5.4.1, 5.4.2) Clinical benefit rate (CBR) from PIs + IMiDs + DEX and PIs + alkylating agent + DEX. CI, 95% confidence interval; Random, random-effects model

Full size image
Fig. 6
figure 6

Meta-analysis of carfilzomib-containing regimens vs. standard chemotherapy for relapsed/refractory multiple myeloma in terms of response outcomes. (6.1.1) Overall response rate (ORR) analysis. (6.1.2) Very good partial response or better rate (≥ VGPR) analysis. (6.1.3) Complete response or better rate (≥ CR) analysis. (6.1.3) Clinical benefit rate (CBR) analysis. CI, 95% confidence interval; Random, random-effects model

Full size image

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, W., Sun, X., Wang, B. et al. Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma. Ann Hematol 97, 299–307 (2018). https://doi.org/10.1007/s00277-017-3173-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-017-3173-9

Keywords

Search

Navigation